2019-03-28
Proteo’s Elafin Enters The Clinic For Subcutaneous Use In Pulmonary Arterial Hypertension
The Company's focus is on the development of anti-inflammatory treatments for rare diseases with significant unmet needs. Proteo is engaged in the development of pharmaceuticals based on the body's own tools and weapons to fight inflammatory diseases.
2019-03-28
Proteo’s Elafin Enters The Clinic For Subcutaneous Use In Pulmonary Arterial Hypertension
